Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Atezolizumab for PD-L1–Selected Patients with NSCLC
Ist Teil von
The New England journal of medicine, 2021-02, Vol.384 (6), p.583-585
Ort / Verlag
United States: Massachusetts Medical Society
Erscheinungsjahr
2021
Quelle
MEDLINE
Beschreibungen/Notizen
To the Editor:
In the recent article by Herbst et al. (Oct. 1 issue)
1
regarding a trial of single-agent atezolizumab for first-line treatment of programmed death ligand 1 (PD-L1)–selected patients with non–small-cell lung cancer (NSCLC), Figure 1 did not show specific survival data for patients with intermediate PD-L1 expression (i.e., those with expression on ≥5% of tumor cells or tumor-infiltrating immune cells but not meeting the definition of high expression) or low PD-L1 expression (expression on ≥1% and <5% of tumor cells or tumor-infiltrating cells). Therefore, we have reconstructed the hazard ratios for overall survival in these subgroups from their . . .